• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant

 

AI ‘s Role in Drug Discovery: Separating the Hype from the Hope

by Jonathan Montague, President & CEO at HotSpot Therapeutics 11/03/2022 Leave a Comment

Jonathan Montague, President & CEO at HotSpot Therapeutics

Forecasting the influence that artificial intelligence (AI)/machine learning technologies will have on the future of healthcare has created a cottage industry in the hype. From the overzealous aspirations of IBM’s Watson Health initiative to the inclusion of AI on Gartner’s 2021 Hype Cycle at the “Peak of Inflated Expectations,” so much noise has been made around AI/machine learning in healthcare that it can be difficult to appreciate the current impact of these technologies on drug discovery,
Read More

JPMorgan Establishes Life Sciences Private Equity Division

by Fred Pennic 11/02/2022 Leave a Comment

JPMorgan Establishes Life Sciences Private Equity Division

What You Should Know: - J.P. Morgan Asset Management announced the establishment of a new life sciences private equity team, Life Sciences Private Capital. - The new team will focus on investing in both early and growth-stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity,
Read More

The Gains and Pains of Using AI in the Pharmaceutical Industry

by Michael Galarnyk, AI Evangelist at cnvrg.io 10/25/2022 Leave a Comment

The Gains and Pains of Using AI in the Pharmaceutical Industry

The costs for drug discovery and development are skyrocketing, but AI (artificial intelligence) is introducing new efficiencies to help find effective treatments faster. A study in 2020 concluded that the estimated median capitalized research and development cost per product was $985 million. Contributing factors to this included larger trial sizes, the need to assess health technology, the requirement to provide data on comparative drugs’ effectiveness, and most
Read More

Biotech Startup Obatala Sciences Raises $3M for Organ-on-a-Chip for Research

by Syed Hamza Sohail 10/14/2022 Leave a Comment

Biotech Startup Obatala Sciences Raises $3M for Organ-on-a-Chip for Research

What You Should Know: - Obatala Sciences, a New Orleans biotechnology company recognized for speeding up therapies for obesity, diabetes, and cancer across diverse populations, recently announced the closing of a $3 million Series A finance round co-led by être Venture Capital and Ochsner Lafayette General Healthcare Innovation Fund II and joined by Benson Capital Partners, Elevate Capital Fund, and The Hackett-Robertson-Tobe Group. - The funding will be used to further the
Read More

Pretzel Therapeutics Launches With $72.5M to Pioneer Mitochondrial Therapies

by Syed Hamza Sohail 09/20/2022 Leave a Comment

Pretzel Therapeutics Launches With $72.5M to Pioneer Mitochondrial Therapies

What You Should Know: - Pretzel Therapeutics, a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, launched today with $72.5M in Series A financing to pioneer novel therapies to modulate mitochondrial function. - The financing was led by ARCH Venture Partners and Mubadala Capital with participating investors HealthCap, Cambridge Innovation Capital, Cambridge Enterprise, Angelini Ventures, GV, Invus, Eir Ventures, GU Ventures, and
Read More

Merck Digital Sciences Studio Launches to Support Biomedical Startups

by Fred Pennic 06/29/2022 Leave a Comment

Merck Digital Sciences Studio Launches to Support Biomedical Startups

What You Should Know: - Merck, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development. - MDSS will support early-stage biomedical startups with direct investment, access to powerful Azure Cloud computing and opportunities to pilot their technologies in collaboration with discovery and clinical scientists at Merck. MDSS Accelerator Program Focus The MDSS is a collaboration between
Read More

Insilico Medicine Raises $60M, Launches AI-powered Drug Discovery Robotics Laboratory

by Fred Pennic 06/06/2022 Leave a Comment

Insilico Medicine Raises $60M, Launches AI-powered Drug Discovery Robotics Laboratory

What You Should Know: - Insilico Medicine, an NYC-based clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company raises $60 million in Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors. - Insilico is also launching a new state-of-the-art robotics lab and fully robotic biological data factory. They have seen a string of successes thus far in 2022, including the
Read More

Buried Under Dirt or Under Debt: Can Patients Survive the Struggle of Getting Care?

by Srulik Dvorsky, TailorMed CEO and Founder 05/25/2022 Leave a Comment

BURIED UNDER DIRT OR UNDER DEBT: Can Patients Survive the Struggle of Getting Care?

New patients at a cancer center in Michigan receive a 79-page handbook when their treatments commence. The handbook includes needed advice on what to eat and the side effects of chemotherapy drugs. One double-sided page features information about how to navigate the financial aspects of cancer treatment, including who to contact for help with medical bills.  For Leslie Vreeland-Corpe of Michigan, one double-sided page couldn’t contain all the information she needed. After being diagnosed
Read More

Eli Lilly Partners with Yseop to Expedite Drug Approval Process

by Strategic Partnerships 05/18/2022 Leave a Comment

Eli Lilly Partners with Yseop to Expedite Drug Approval Process

What You Should Know: - Eli Lilly and Company partners with Yseop, an AI software company and pioneer in Natural Language Processing (NLP) to deploy Yseop’s world-class enterprise automation platform, Augmented Analyst, to accelerate bringing Lilly’s medicines to patients. - Yseop’s platform uses Natural Language Generation (NLG) to augment human analysis with automated insights. With Yseop’s powerful AI automation technology, teams can shorten the time spent on specialist medical reports
Read More

Character Biosciences Raises $18M to Expand Precision Medicine Platform for Diseases of Aging

by Fred Pennic 05/17/2022 Leave a Comment

Character Biosciences Raises $18M to Expand Precision Medicine Platform for Diseases of Aging

What You Should Know: - Character Biosciences (“Character”), a precision medicine platform for diseases of aging raises $18M in a new funding round led by Innovation Endeavors, alongside leading life sciences investors Section 32 and Catalio Capital Management. Formerly known as Clover Therapeutics, the company’s data-driven approach integrates genomics, deep phenotyping and machine learning for target and biomarker discovery. - The company will use the funding to advance the frontiers of
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 5
  • Go to page 6
  • Go to page 7
  • Go to page 8
  • Go to page 9
  • Interim pages omitted …
  • Go to page 13
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Moving Beyond EHRs: What Lies Ahead for Healthcare Digitization?

AI Agents vs. Chatbots: Understanding Agentic AI’s Role in Healthcare

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

AI Breakthrough Reveals 2025 AI Breakthrough Award Winners

Healthcare's Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Healthcare’s Big Blind Spot: The Measurement Crisis in Inpatient Psychiatry

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |